Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > When a long-awaited tech launches...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(131)
•••
Comment by gojotv!on Sep 14, 2021 11:07am
117 Views
Post# 33854760

RE:RE:When a long-awaited tech launches...

RE:RE:When a long-awaited tech launches...That's funny, Againstallodds, because the trend for SZLS is up, while PYR is down.
And you don't seem to find our multi-aliased basher annoying, just the person who sees where this stock is going. Up.
I don't see you criticizing that pathological liar, UncleRon, on the PYR board.
Well, I'm sorry if you find the truth irritating.
Fact is, SZLS is paying off in the short run, while PYR could be a decent bet early next year. Bagholder stuff for the moment.
It's only being sustained by pumpers right now.
Just the facts, man.


Againstallodds2 wrote: I dont know about everyone else that reads this board but I'm real sick and tired of seeing your pointless pumper posts. The fact that your still pumping this stock and bashing pyrogenesis is mind boggling.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities